ELVN
NASDAQEnliven Therapeutics Inc.
Price$48.58+18.56 (+61.81%)
2026-03-192026-06-23
News · 26 weeks72+214%
2025-12-282026-06-21
Mix3490d
- SEC Filings16(47%)
- Insider7(21%)
- Other4(12%)
- Offering3(9%)
- Analyst2(6%)
- Earnings2(6%)
Latest news
25 items- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin exercised 6,018 shares at a strike of $2.48 and sold $263,577 worth of shares (6,018 units at $43.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise sold $219,017 worth of shares (5,000 units at $43.80) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERLarge owner Orbimed Advisors Llc sold $12,668,988 worth of shares (281,408 units at $45.02) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Enliven Therapeutics Inc.SCHEDULE 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- PREnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesBURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, wh
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECSEC Form 424B5 filed by Enliven Therapeutics Inc.424B5 - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsBURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven's common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common
- SECSEC Form 424B5 filed by Enliven Therapeutics Inc.424B5 - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIsFavorable safety and tolerability profile with 161 patients enrolled and a median treatment duration of 35 weeksAlignment with the FDA on 80 mg QD as the recommended Phase 3 dose and on the 2L+ patient population for the ENABLE-2 pivotal trial, which is expected to initiate in the second half of this year BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discov
- INSIDERDirector Kunkel Lori Anne sold $345,351 worth of shares (10,000 units at $34.54) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 51,884 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- ANALYSTStifel initiated coverage on Enliven Therapeutics with a new price targetStifel initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $60.00
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
- PREnliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 CongressEnliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will host a webcast conference call on Thursday, June 11, 2026 at 8:30 a.m. ET to discuss updated data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML) that will be presented at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden, and vi
- PREnliven Therapeutics to Present at Upcoming Investor ConferencesBOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m. ETJefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 11:40 a.m. ETThe fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherape
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise sold $198,971 worth of shares (5,000 units at $39.79) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $2.48 (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- PREnliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CMLAbstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohortIn patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeksELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients and longer treatment durationBOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the dis
ELVN FAQ
6 questionsWhere does ELVN stock trade?
Enliven Therapeutics Inc. (ELVN) is listed on NASDAQ.What sector and industry is ELVN in?
Enliven Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enliven Therapeutics Inc. go public?
Enliven Therapeutics Inc. (ELVN) completed its IPO in 2020.What are analysts saying about ELVN?
Enliven Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2026-06-09. Recent price targets range from $2700.00 to $4200.00.What companies are similar to ELVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ELVN side-by-side with any of them on Quantisnow.How can I track ELVN on Quantisnow?
Quantisnow aggregates Enliven Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELVN to receive live email and push alerts on every new disclosure.